IMCR
Immunocore·NASDAQ
--
--(--)
--
--(--)
IMCR fundamentals
Immunocore (IMCR) Revenue Breakdown: Q3 2025 Business & Regional Performance
Immunocore (IMCR) reported total revenue of 103.69M USD in Q3 2025, with its core business segment Revenue From Sale of Therapies, Net contributing 100.00%. Regionally, United States remained the largest market, accounting for 64.90% of total revenue. Explore Immunocore's revenue distribution across business segments and global markets to gain insights into its growth trends and market position.
Immunocore (IMCR) reported total revenue of 103.69M USD in Q3 2025, with its core business segment Revenue From Sale of Therapies, Net contributing 100.00%. Regionally, United States remained the largest market, accounting for 64.90% of total revenue. Explore Immunocore's revenue distribution across business segments and global markets to gain insights into its growth trends and market position.
By Business
No Data
By Region
No Data
You can ask Aime
What is the revenue and EPS growth rate for Immunocore year over year?What is Immunocore's latest dividend and current dividend yield?What factors drove the changes in Immunocore's revenue and profit?What were the key takeaways from Immunocore's earnings call?What guidance did Immunocore's management provide for the next earnings period?What is Immunocore's gross profit margin?What were the key takeaways from Immunocore’s earnings call?Did Immunocore beat or miss consensus estimates last quarter?
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
